以生物标志物为导向的化学免疫疗法用于晚期胃癌
Koji Kono1, Shotaro Nakajima2,3, Kosaku Mimura2,4
1Department of Gastrointestinal Tract Surgery, Fukushima Medical University School of Medicine, Fukushima City, Fukushima, 960-1295, Japan. kojikono@fmu.ac.jp.
International journal of clinical oncology
|April 22, 2024
概括
生物标志物驱动的疗法正在推进胃癌治疗. 本次审查强调了针对向抗癌药物开发的HER2,PD-L1和Claudin18.2等关键生物标志物.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 以生物标志物为导向的化疗免疫疗法通过丰富患者的反应来显示抗癌药物开发的前景.
- 与其他癌症 (如结肠直肠癌和肺癌) 相比,胃癌的生物标志物驱动疗法的发展滞后.
- 最近的发现和临床试验正在推动胃癌的向治疗.
研究的目的:
- 审查胃癌中重要的生物标志物.
- 讨论这些生物标志物的临床意义.
- 为了突出相关的向治疗剂.
主要方法:
- 关于胃癌生物标志物的最近研究的文献综述.
- 对生物标志物驱动疗法的临床试验数据的分析.
- 专注于人类表皮生长因子受体2 (HER2),编程死亡配体1 (PD-L1) 和Claudin18.2.2.
主要成果:
- HER2,PD-L1和Claudin18.2是胃癌中的关键生物标志物.
- 这些生物标志物在患者分层方面已显示出临床意义.
- 与这些生物标志物相关的向药物提供了新的治疗选择.
结论:
- 个性化,以生物标志物为导向的策略正在成为胃癌治疗的可行性.
- 基于HER2,PD-L1和Claudin18.2的向疗法是一个有希望的前沿.
- 对生物标志物发现和向药物的持续研究对于推进胃癌治疗至关重要.
相关概念视频
01:27Tumor Immunotherapy
522
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
522
02:57Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K